289 related articles for article (PubMed ID: 27699576)
1. Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
Marchica V; Accardi F; Storti P; Mancini C; Martella E; Dalla Palma B; Bolzoni M; Todoerti K; Marcatti M; Schifano C; Bonomini S; Sammarelli G; Neri A; Ponzoni M; Aversa F; Giuliani N
Int J Hematol; 2017 Jan; 105(1):104-108. PubMed ID: 27699576
[TBL] [Abstract][Full Text] [Related]
2. [Secondary cutaneous plasmacytoma revealing multiple myeloma: about a case].
Ngolet LO; N'soundhat NL; Ndounga E; Kocko I; Kidédé DC; Ntsiba H
Pan Afr Med J; 2016; 24():44. PubMed ID: 27642385
[TBL] [Abstract][Full Text] [Related]
3. Resident Rounds: Part III--Case Report: Metastatic Multiple Myeloma.
Scott JF; Merati M; Honda K; Cooper KD; Reichert B
J Drugs Dermatol; 2015 Dec; 14(12):1485-6. PubMed ID: 26741539
[TBL] [Abstract][Full Text] [Related]
4. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
[TBL] [Abstract][Full Text] [Related]
5. Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head.
Sun WJ; Zhang JJ; An N; Shen M; Huang ZX; Li X
J Int Med Res; 2016 Dec; 44(6):1462-1473. PubMed ID: 28322099
[TBL] [Abstract][Full Text] [Related]
6. Case for diagnosis. Cutaneous involvement associated to multiple myeloma.
Santos G; Sousa L; Fernandes T; João A
An Bras Dermatol; 2014; 89(1):173-4. PubMed ID: 24626671
[TBL] [Abstract][Full Text] [Related]
7. Metastatic cutaneous plasmacytoma: a case report associated with IgA lambda multiple myeloma and a review of the literature of metastatic cutaneous plasmacytomas associated with multiple myeloma and primary cutaneous plasmacytomas.
Kato N; Kimura K; Yasukawa K; Aikawa K
J Dermatol; 1999 Sep; 26(9):587-94. PubMed ID: 10535253
[TBL] [Abstract][Full Text] [Related]
8. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
[TBL] [Abstract][Full Text] [Related]
9. Extramedullary cutaneous plasmacytoma.
Ceccolini E; Palmerio B; Patrone P
Cutis; 1991 Aug; 48(2):134-6. PubMed ID: 1935238
[TBL] [Abstract][Full Text] [Related]
10. Metastatic cutaneous plasmacytoma presenting as a perianal giant mass.
Alvarez-Twose I; Vano-Galvan S; Calvo-Villas JM; Carreter E; Piqué E; Palacios S
Dermatol Online J; 2008 Sep; 14(9):17. PubMed ID: 19061599
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous plasmacytoma.
Matsuda M; Sueda S; Taniguchi T
Int J Hematol; 2017 May; 105(5):545-546. PubMed ID: 28247190
[No Abstract] [Full Text] [Related]
12. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I
Leuk Lymphoma; 2001 Aug; 42(4):683-7. PubMed ID: 11697498
[TBL] [Abstract][Full Text] [Related]
13. Extramedullary gastric plasmacytoma.
Hamilton JW; McCluggage WG; Jones F; Collins J
Ulster Med J; 1999 Nov; 68(2):103-5. PubMed ID: 10661638
[No Abstract] [Full Text] [Related]
14. Disseminated growth of murine plasmacytoma: similarities to multiple myeloma.
Roschke V; Hausner P; Kopantzev E; Pumphrey JG; Riminucci M; Hilbert DM; Rudikoff S
Cancer Res; 1998 Feb; 58(3):535-41. PubMed ID: 9458102
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous metastatic plasmacytomas with tropism for a previously injured limb.
Pereira MA; Baudrier T; Costa A; Magalhães J; Azevedo F
Dermatol Online J; 2008 Sep; 14(9):16. PubMed ID: 19061598
[TBL] [Abstract][Full Text] [Related]
16. Myeloma escape from immunity: an "inside" job.
Rapoport AP
Blood; 2015 Sep; 126(12):1401-3. PubMed ID: 26384282
[TBL] [Abstract][Full Text] [Related]
17. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.
Bladé J; Perales M; Rosiñol L; Tuset M; Montoto S; Esteve J; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E
Br J Haematol; 2001 May; 113(2):422-4. PubMed ID: 11380408
[TBL] [Abstract][Full Text] [Related]
19. Initial bone marrow findings in multiple myeloma. Significance of plasma cell nodules.
Buss DH; Prichard RW; Hartz JW; Cooper MR; Feigin GA
Arch Pathol Lab Med; 1986 Jan; 110(1):30-3. PubMed ID: 3753566
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic study of cutaneous plasmacytoma.
Torne R; Su WP; Winkelmann RK; Smolle J; Kerl H
Int J Dermatol; 1990 Oct; 29(8):562-6. PubMed ID: 2242944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
